Label: BYNFEZIA PEN- octreotide acetate injection

  • NDC Code(s): 62756-452-36, 62756-452-37
  • Packager: Sun Pharmaceutical Industries, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated February 21, 2025

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use BYNFEZIA PEN safely and effectively. See full prescribing information for BYNFEZIA PEN.   BYNFEZIA PEN® (octreotide acetate ...
  • Table of Contents
    Table of Contents
  • 1 INDICATIONS AND USAGE
    1.1 Acromegaly - BYNFEZIA PEN is indicated to reduce blood levels of growth hormone (GH) and insulin gro wth factor-1 (I GF-1; somatomedin C) in acromegaly patients who have had inadequate ...
  • 2 DOSAGE AND ADMINISTRATION
    2.1 Dosage and Administration Overview - Inspect visually for particulate matter and discoloration. Only use BYNFEZIA PEN if the solution appears colorless with no visible particles. BYNFEZIA ...
  • 3 DOSAGE FORMS AND STRENGTHS
    BYNFEZIA PEN is available as: Injection: 7,000 mcg/2.8 mL (2,500 mcg/mL) octreotide (as acetate) as a clear, colorless solution in a single-patient-use prefilled pen.
  • 4 CONTRAINDICATIONS
    Sensitivity to this drug or any of its co mponents.
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Cardiac Conduction Abnormalities - Cardiac conduction abnormalities have occurred during treatment with octreotide. In acromegalic patients, bradycardia (< 50 bpm) developed in 25% ...
  • 6 ADVERSE REACTIONS
    The following clinically significant adverse reactions are described elsewhere in the labeling: Cardiac Conduction Abnormalities [Warnings and Precautions (5.1)] Cholelithiasis and ...
  • 7 DRUG INTERACTIONS
    7.1 Cyclosporine - Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Concomitant administration of ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - The limited data with octreotide acetate in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.   In animal ...
  • 10 OVERDOSAGE
    A limited number of accidental overdoses of octreotide in adults have been reported. In adults, the doses ranged from 2,400 to 6,000 mcg/day administered by continuous infusion (100 to 250 ...
  • 11 DESCRIPTION
    BYNFEZIA PEN (octreotide acetate) injection contains octreotide as its acetate salt.  Octreotide is a somatostatin analogue. Octreotide acetate known chemically as L-Cysteinamide ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - BYNFEZIA PEN (octreotide acetate) exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - Studies in laboratory animals have demonstrated no mutagenic potential of octreotide injection. No carcinogenic potential was ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    How Supplied - BYNFEZIA PEN ( octreotide acetate) injection, 7,000 mcg/2.8 mL (2,500 mcg /mL) octreotide is a clear colorless solution and it is available as:   Dosage Unit - Package ...
  • 17 PATIENT COUNSELING INFORMATION
    Advise patient and/or caregivers to read the FDA-approved patient labeling (Instructions for Use). Sterile Subcutaneous Injection Technique - Careful instruction in sterile subcutaneous injection ...
  • INSTRUCTIONS FOR USE
    BYNFEZIA PEN® (ben-FEZ-ee-uh PEN) (octreotide acetate) Prefilled Pen - Read these instructions before you start using the BYNFEZIA PEN. It is important that you understand and follow these ...
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
    Rx only - NDC 62756-452-37 - Bynfezia Pen®  (octreotide acetate Injection) 7,000 mcg/2.8mL (2,500 mcg/mL) Two 2.8 mL disposable single-patient-use prefilled pens - Subcutaneous use only ...
  • INGREDIENTS AND APPEARANCE
    Product Information